The Basal Ganglia

The basal ganglia are a group of subcortical nuclei that orchestrate the selection and modulation of voluntary movements. The most clinically prominent of all neurological diseases — Parkinson disease, Huntington disease, dystonia, the various forms of chorea and ballism — are diseases of basal ganglia circuits. Beyond the motor system, the basal ganglia participate in cognitive and limbic circuits that influence executive function, emotion, and motivation. Understanding the architecture of these nuclei and the loops they form with cortex and thalamus is essential for understanding both the motor disorders that dominate movement neurology and the cognitive-behavioral consequences of subcortical disease.

This page covers the anatomy of the basal ganglia nuclei, the direct and indirect pathways through them, the parallel cortical-basal ganglia-thalamic loops, and the disorders that arise when these circuits fail. The point is to give the trainee a framework for understanding how a relatively small group of nuclei produces such a wide range of clinical phenotypes.

Anatomical Composition

The basal ganglia comprise five nuclei, four of which sit in the cerebral hemisphere and one (the substantia nigra) in the midbrain:

  • Caudate nucleus: C-shaped, following the curve of the lateral ventricle. Head, body, and tail.
  • Putamen: lateral, lying just deep to the insula.
  • Globus pallidus: medial to the putamen, divided into external (GPe) and internal (GPi) segments.
  • Subthalamic nucleus (STN): small, lens-shaped, just below the thalamus.
  • Substantia nigra: in the midbrain, divided into pars compacta (SNc, dopaminergic) and pars reticulata (SNr, GABAergic, functionally similar to GPi).

Several composite terms based on anatomy and function:

  • Striatum (neostriatum): caudate + putamen. The principal input nucleus of the basal ganglia, receiving input from essentially the entire cerebral cortex.
  • Lentiform (lenticular) nucleus: putamen + globus pallidus together (so named for their lens shape on cross-section).
  • Corpus striatum: caudate + lentiform nucleus (an older anatomical term).
  • Pallidum: globus pallidus, with its two segments.
  • Ventral striatum: includes the nucleus accumbens — important for limbic and reward processing.

The Three Main Circuits

The basal ganglia participate in three major cortical-subcortical loops, distinguished by which cortical regions and thalamic nuclei are involved:

  • Motor loop: from motor and premotor cortex through putamen, globus pallidus, ventral lateral and ventral anterior thalamus, back to motor cortex. Modulates voluntary movement selection.
  • Associative (cognitive) loop: from association cortex through caudate, globus pallidus, mediodorsal thalamus, back to prefrontal cortex. Modulates executive function and goal-directed behavior.
  • Limbic loop: from limbic cortex through ventral striatum (including nucleus accumbens), ventral pallidum, mediodorsal thalamus, back to cingulate and orbitofrontal cortex. Modulates motivation, reward, and emotional behavior.

All three loops share the same general architecture and the same intrinsic basal ganglia circuitry; they differ in which cortical regions they connect.

The Direct and Indirect Pathways

Within each loop, the basal ganglia have two pathways that have opposite effects on movement: the direct pathway (which facilitates movement) and the indirect pathway (which inhibits unwanted movements). Both pathways converge on the output nuclei of the basal ganglia (GPi and SNr), which provide tonic inhibition to the thalamus.

Tonic State

At rest, the output nuclei (GPi/SNr) tonically inhibit the thalamus, which in turn reduces excitatory drive to motor cortex. The basal ganglia therefore actively suppress unwanted movements.

Direct Pathway (Facilitates Desired Movement)

  1. Cortex sends glutamatergic excitation to striatum (medium spiny neurons expressing D1 receptors).
  2. These neurons send GABAergic inhibition to GPi/SNr.
  3. GPi/SNr inhibition is reduced, which disinhibits the thalamus.
  4. Thalamus excites motor cortex more, facilitating the desired movement.

The direct pathway is reinforced by dopamine acting on D1 receptors on the striatal output neurons.

Indirect Pathway (Suppresses Unwanted Movements)

  1. Cortex sends glutamatergic excitation to striatum (medium spiny neurons expressing D2 receptors).
  2. These neurons send GABAergic inhibition to GPe.
  3. GPe inhibition of subthalamic nucleus (STN) is reduced; STN becomes more active.
  4. STN sends glutamatergic excitation to GPi/SNr.
  5. GPi/SNr output to thalamus is increased, increasing thalamic inhibition.
  6. Reduced thalamic excitation of motor cortex, suppressing competing movements.

The indirect pathway is opposed by dopamine acting on D2 receptors on the striatal output neurons (D2 activation reduces this pathway’s effect).

The Net Effect of Dopamine

Dopamine from the substantia nigra pars compacta acts on both D1 receptors (facilitating direct pathway, promoting movement) and D2 receptors (inhibiting indirect pathway, removing brake on movement). In both cases, dopamine promotes movement. Loss of dopamine — as in Parkinson disease — therefore produces movement deficits (bradykinesia, rigidity, tremor) through reduced direct pathway and increased indirect pathway activity.

The Substantia Nigra and Dopaminergic Projections

The substantia nigra pars compacta contains the dopaminergic neurons whose loss defines Parkinson disease. Three major dopaminergic projection systems originate near here:

  • Nigrostriatal: from SNc to dorsal striatum (putamen and caudate). The principal target of Parkinson disease pathology. Loss produces motor symptoms.
  • Mesolimbic: from ventral tegmental area (VTA, adjacent to SNc) to nucleus accumbens and other limbic structures. Involved in reward, motivation, addiction.
  • Mesocortical: from VTA to prefrontal cortex. Involved in cognition and executive function.

Antipsychotic drugs block dopamine D2 receptors, with effects on all three systems. The desired effects in psychosis are mediated through mesolimbic and mesocortical pathways; the parkinsonian side effects through nigrostriatal blockade; the hyperprolactinemia side effect through tuberoinfundibular blockade.

Vascular Supply

The basal ganglia receive their blood supply primarily from small perforating arteries:

  • Lenticulostriate arteries: small branches from the M1 segment of the middle cerebral artery, supplying most of the putamen, the lateral globus pallidus, the caudate body, and the internal capsule. Occlusion produces lacunar infarcts.
  • Recurrent artery of Heubner (medial lenticulostriate artery): from the A2 segment of the anterior cerebral artery, supplying the caudate head and the anterior limb of the internal capsule.
  • Anterior choroidal artery: from the internal carotid (just distal to the posterior communicating artery), supplying parts of the globus pallidus, internal capsule, and lateral geniculate.
  • Thalamoperforator arteries: from the PCA, supplying the subthalamic nucleus.

The lenticulostriate vessels are the typical site of hypertensive intracerebral hemorrhage, with the putamen being the most common location for spontaneous intracerebral hemorrhage in hypertensive patients.

Diseases of the Basal Ganglia

Parkinson Disease

Progressive loss of dopaminergic neurons in the substantia nigra pars compacta, producing the cardinal features: bradykinesia, rest tremor, rigidity, and (later) postural instability. The pathology is alpha-synuclein aggregation (Lewy bodies). Treatment focuses on restoring dopaminergic function with levodopa, dopamine agonists, MAO-B inhibitors, and (in advanced cases) deep brain stimulation of the subthalamic nucleus or globus pallidus internus.

Huntington Disease

Autosomal dominant; CAG repeat expansion in the HTT gene. Pathology begins in the striatum, particularly the medium spiny neurons of the indirect pathway. Loss of these neurons disinhibits the GPe, ultimately producing hyperkinetic movements (chorea) early. As the disease progresses, more neurons are lost, and rigidity may eventually predominate. Cognitive decline (executive dysfunction prominent) and psychiatric features (depression, irritability, sometimes psychosis) accompany the motor symptoms. Onset is typically in middle age, with juvenile forms presenting with rigidity rather than chorea.

Wilson Disease

Autosomal recessive; mutations in the ATP7B copper transporter produce copper accumulation in liver, brain, and other organs. Neurological presentation often includes dystonia, tremor, dysarthria, and parkinsonism — sometimes with a characteristic “wing-beating” tremor. Kayser-Fleischer rings (corneal copper deposition) are highly suggestive. Always consider Wilson disease in any young person with movement disorder, hepatic dysfunction, or psychiatric symptoms — the diagnosis is treatable.

Dystonia

Sustained muscle contractions producing twisting movements or abnormal postures. May be focal (cervical dystonia, blepharospasm), segmental, hemidystonia, or generalized. Causes include primary genetic dystonias (DYT1 and others), acquired dystonia (after stroke, trauma, perinatal injury), drug-induced (acute dystonic reactions, tardive dystonia), and dystonia-plus syndromes (dopa-responsive dystonia, myoclonus-dystonia). Pathophysiology involves abnormal basal ganglia output, often with cerebellar contributions in some forms. Treatment varies: focal dystonias often respond to botulinum toxin; generalized dystonia may benefit from anticholinergics or deep brain stimulation of the globus pallidus internus.

Hemiballism

Large-amplitude flinging movements of a proximal limb, classically from a contralateral subthalamic nucleus lesion (most often a small lacunar stroke). The subthalamic lesion releases the indirect pathway’s brake on movement, producing the characteristic involuntary movements. Treatment is symptomatic; the condition often improves spontaneously over weeks to months.

Tardive Dyskinesia

Involuntary movements, classically oral-buccal-lingual (lip smacking, tongue protrusion, chewing movements), after chronic exposure to dopamine receptor antagonists (antipsychotics, metoclopramide). The mechanism is thought to involve dopamine receptor supersensitivity after chronic D2 blockade. Treatment is difficult; vesicular monoamine transporter (VMAT2) inhibitors (valbenazine, tetrabenazine) have shown efficacy.

Drug-Induced Parkinsonism

Dopamine receptor antagonists produce a parkinsonian syndrome that is often symmetric (in contrast to the asymmetric onset of idiopathic PD). Common culprits: haloperidol, risperidone, metoclopramide, prochlorperazine. Discontinuation of the offending agent generally produces resolution over weeks to months.

Hepatocerebral Degeneration

Chronic liver disease produces basal ganglia manganese deposition with characteristic T1 hyperintensity in the globus pallidus and substantia nigra on MRI. Clinical manifestations include parkinsonism, dystonia, and cognitive changes.

NBIA (Neurodegeneration with Brain Iron Accumulation)

A family of rare genetic disorders producing iron deposition in the basal ganglia, with characteristic “eye-of-the-tiger” sign on MRI of the globus pallidus (in pantothenate kinase-associated neurodegeneration, PKAN). Various movement disorders (dystonia, parkinsonism, chorea) accompany cognitive decline.

Stereotactic Surgery for Movement Disorders

Deep brain stimulation (DBS) has revolutionized treatment of refractory movement disorders. Common targets:

  • Subthalamic nucleus (STN): for Parkinson disease. Reduces motor symptoms and allows reduction of levodopa dose.
  • Globus pallidus internus (GPi): for Parkinson disease and dystonia. Particularly effective in primary generalized dystonia.
  • Ventral intermediate (Vim) nucleus of the thalamus: for essential tremor and parkinsonian tremor.
  • Anterior thalamic nucleus: for refractory focal epilepsy.
  • Centromedian-parafascicular complex: investigational for various conditions.

DBS is reversible (unlike lesional surgery), with parameters adjustable to optimize benefit and minimize side effects.

🔍 Did You Know?

The classical “model” of basal ganglia function — separate direct and indirect pathways with opposing effects on movement — was developed in the 1980s and remains the central organizing principle, but it has been substantially refined. The pathways are not as strictly separated as originally proposed: many striatal neurons participate in both pathways, dopamine acts through receptors beyond the classical D1 and D2, and the subthalamic nucleus has a “hyperdirect” pathway from cortex that bypasses the striatum entirely. The clinical implications of this refined understanding are still being worked out, but the basic message of the original model — that the basal ganglia balance facilitating and inhibiting pathways to control movement selection — remains accurate and useful at the bedside.

Pitfalls and Pearls

  • The basal ganglia are organized into parallel cortical-subcortical loops for motor, cognitive, and limbic functions.
  • Direct pathway facilitates movement; indirect pathway suppresses it. Both converge on GPi/SNr output.
  • Dopamine promotes movement through D1 receptors (enhancing direct pathway) and D2 receptors (inhibiting indirect pathway). Loss of dopamine (PD) reduces movement.
  • Parkinson disease is loss of nigrostriatal dopamine. Symmetric onset, early postural instability, and severe autonomic features should raise suspicion for atypical parkinsonism.
  • Huntington disease begins with indirect pathway striatal loss, producing chorea. As more neurons are lost, rigidity may predominate.
  • Wilson disease is treatable; always check ceruloplasmin and 24-hour urine copper in any young person with a movement disorder.
  • Hemiballism is contralateral subthalamic lesion, classically lacunar stroke. Often improves spontaneously.
  • Tardive dyskinesia from long-term antipsychotic use can persist after the offending drug is stopped. VMAT2 inhibitors (valbenazine, tetrabenazine) are the new treatments.
  • The lenticulostriate arteries are the typical site of hypertensive intracerebral hemorrhage, with the putamen being the most common location.
  • DBS of STN or GPi can dramatically improve Parkinson disease when medications no longer control symptoms; patient selection matters.

References

  1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-375.
  2. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64(1):20-24.
  3. Lang AE, Lozano AM. Parkinson’s disease. N Engl J Med. 1998;339(15):1044-1053.
  4. Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218-228.
  5. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-142.
  6. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-873.